Quidel Corp. (QDEL) SVP John Tamerius Sells 8,878 Shares
Quidel Corp. (NASDAQ:QDEL) SVP John Tamerius sold 8,878 shares of the firm’s stock in a transaction dated Friday, November 25th. The stock was sold at an average price of $23.50, for a total transaction of $208,633.00. Following the transaction, the senior vice president now directly owns 32,418 shares of the company’s stock, valued at $761,823. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Shares of Quidel Corp. (NASDAQ:QDEL) opened at 22.63 on Wednesday. The firm’s market cap is $738.71 million. The company’s 50 day moving average is $21.20 and its 200-day moving average is $20.26. Quidel Corp. has a 12 month low of $13.21 and a 12 month high of $23.94.
Quidel Corp. (NASDAQ:QDEL) last released its earnings results on Wednesday, October 26th. The company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.12. The business earned $49.30 million during the quarter, compared to the consensus estimate of $50.88 million. Quidel Corp. had a negative net margin of 6.40% and a negative return on equity of 0.81%. The company’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.05) EPS. Equities research analysts predict that Quidel Corp. will post ($0.16) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This piece was first reported by Financial Market News and is the propert of of Financial Market News. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The correct version of this piece can be read at http://www.financial-market-news.com/quidel-corp-qdel-svp-john-tamerius-sells-8878-shares/1210284/.
A number of research firms have recently commented on QDEL. Zacks Investment Research raised shares of Quidel Corp. from a “sell” rating to a “hold” rating in a report on Friday, November 4th. Canaccord Genuity set a $22.00 price objective on shares of Quidel Corp. and gave the stock a “hold” rating in a report on Thursday, October 27th. One analyst has rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $21.58.
Hedge funds have recently added to or reduced their stakes in the stock. Brown Capital Management LLC increased its stake in Quidel Corp. by 0.4% in the second quarter. Brown Capital Management LLC now owns 5,748,536 shares of the company’s stock worth $102,669,000 after buying an additional 23,100 shares in the last quarter. A.R.T. Advisors LLC increased its stake in Quidel Corp. by 196.5% in the first quarter. A.R.T. Advisors LLC now owns 45,570 shares of the company’s stock worth $786,000 after buying an additional 30,200 shares in the last quarter. Aristotle Capital Boston LLC increased its stake in Quidel Corp. by 3.2% in the second quarter. Aristotle Capital Boston LLC now owns 266,364 shares of the company’s stock worth $4,757,000 after buying an additional 8,338 shares in the last quarter. State Board of Administration of Florida Retirement System increased its stake in Quidel Corp. by 0.4% in the second quarter. State Board of Administration of Florida Retirement System now owns 27,980 shares of the company’s stock worth $500,000 after buying an additional 104 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. increased its stake in Quidel Corp. by 1.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 103,229 shares of the company’s stock worth $1,844,000 after buying an additional 1,782 shares in the last quarter. 92.28% of the stock is owned by institutional investors and hedge funds.
About Quidel Corp.
Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. The Company’s diagnostic testing solutions primarily include applications in infectious diseases, women’s health and gastrointestinal diseases. It sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics and wellness screening centers.
Receive News & Ratings for Quidel Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel Corp. and related companies with MarketBeat.com's FREE daily email newsletter.